JP2004537517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537517A5 JP2004537517A5 JP2002589500A JP2002589500A JP2004537517A5 JP 2004537517 A5 JP2004537517 A5 JP 2004537517A5 JP 2002589500 A JP2002589500 A JP 2002589500A JP 2002589500 A JP2002589500 A JP 2002589500A JP 2004537517 A5 JP2004537517 A5 JP 2004537517A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- myc
- oligomer
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 16
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 14
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 14
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 14
- 230000000692 anti-sense effect Effects 0.000 claims 14
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- MHCMWGPPLOSCJY-UHFFFAOYSA-N 4-$l^{1}-azanylmorpholine Chemical compound [N]N1CCOCC1 MHCMWGPPLOSCJY-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 108091027305 Heteroduplex Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29172701P | 2001-05-17 | 2001-05-17 | |
| PCT/US2002/015842 WO2002092617A1 (en) | 2001-05-17 | 2002-05-17 | Combined approach to treatment of cancer using a c-myc antisense oligomer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537517A JP2004537517A (ja) | 2004-12-16 |
| JP2004537517A5 true JP2004537517A5 (enExample) | 2005-07-28 |
Family
ID=23121574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589500A Pending JP2004537517A (ja) | 2001-05-17 | 2002-05-17 | ｃ−ｍｙｃアンチセンスオリゴマーを使用した、癌を処置するための併用アプローチ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030087861A1 (enExample) |
| EP (1) | EP1399462A4 (enExample) |
| JP (1) | JP2004537517A (enExample) |
| KR (1) | KR20040004629A (enExample) |
| CN (1) | CN1509292A (enExample) |
| CA (1) | CA2447052A1 (enExample) |
| NZ (1) | NZ530101A (enExample) |
| WO (1) | WO2002092617A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7640582B2 (en) | 2003-04-16 | 2009-12-29 | Silicon Graphics International | Clustered filesystem for mix of trusted and untrusted nodes |
| ES2351976T3 (es) | 2003-04-29 | 2011-02-14 | Avi Biopharma, Inc. | Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células. |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| WO2006058038A2 (en) * | 2004-11-22 | 2006-06-01 | The Research Foundation Of State University Of New York At Buffalo | In vitro and in vivo silencing of human c-myc oncogene expression by poly-dnp-rna |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2007064945A2 (en) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
| WO2007065017A2 (en) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Oligonucleotide cationic liposomal delivery system |
| CA2631677C (en) | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
| US20070270371A1 (en) * | 2006-03-31 | 2007-11-22 | Brown Bob D | Dosing and scheduling of oligomers |
| ES2657400T3 (es) * | 2006-05-10 | 2018-03-05 | Sarepta Therapeutics, Inc. | Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| AU2008271050B2 (en) * | 2007-06-29 | 2014-11-06 | Sarepta Therapeutics, Inc. | Tissue specific peptide conjugates and methods |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CN101624596B (zh) * | 2009-08-12 | 2011-01-26 | 广州金琪基因技术研究发展中心 | 一种靶向c-myc癌基因的外指引序列 |
| JP2013530154A (ja) | 2010-05-28 | 2013-07-25 | サレプタ セラピューティクス， インコーポレイテッド | 修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| BR112014011875B1 (pt) | 2011-11-18 | 2022-01-04 | Sarepta Therapeutics, Inc | Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos |
| ITMI20120275A1 (it) | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| WO2016048054A2 (ko) * | 2014-09-24 | 2016-03-31 | 삼성전자 주식회사 | 데이터 통신 보안을 위한 방법, 장치 및 시스템 |
| WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| KR102810425B1 (ko) | 2016-12-19 | 2025-05-21 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| CN108338986B (zh) * | 2017-01-23 | 2020-04-03 | 深圳开悦生命科技有限公司 | 一种用于治疗癌症的小分子rna及其应用 |
| US11987647B2 (en) | 2018-05-09 | 2024-05-21 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| EP3840758A1 (en) * | 2018-08-21 | 2021-06-30 | Deep Genomics Incorporated | Therapeutic splice-switching oligonucleotides |
| CA3126432A1 (en) * | 2019-02-01 | 2020-08-06 | Health Research, Inc. | Methods and compositions for treating resistant and recurrent forms of cancer |
| CN113748209A (zh) | 2019-02-27 | 2021-12-03 | 斯托克制药公司 | 用于治疗病况和疾病的反义寡聚体 |
| AU2021270720A1 (en) | 2020-05-11 | 2022-12-08 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| US12378267B2 (en) | 2021-06-17 | 2025-08-05 | Entrada Therapeutics, Inc. | Synthesis of FMOC-protected morpholino monomers and oligomers |
| WO2023205451A1 (en) | 2022-04-22 | 2023-10-26 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| AU2024222908A1 (en) * | 2023-02-14 | 2025-09-04 | Stoke Therapeutics, Inc. | Antisense oligomer formulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4515781A (en) * | 1983-02-23 | 1985-05-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 2',5'-Riboadenylate-morpholinoadenylate nucleotides |
| US6544755B1 (en) * | 1992-08-26 | 2003-04-08 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of diseases by expression of the c-Myc gene |
| CN1119830A (zh) * | 1993-01-07 | 1996-04-03 | 托马斯·杰弗逊大学 | 反义抑制C-myc以调节平滑肌细胞的增殖 |
| WO1997036005A1 (en) * | 1996-03-26 | 1997-10-02 | Lynx Therapeutics, Inc. | Oligonucleotide treatments and compositions for human melanoma |
| US6784291B2 (en) * | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
-
2002
- 2002-05-17 CN CNA028100719A patent/CN1509292A/zh active Pending
- 2002-05-17 KR KR10-2003-7014985A patent/KR20040004629A/ko not_active Ceased
- 2002-05-17 WO PCT/US2002/015842 patent/WO2002092617A1/en not_active Ceased
- 2002-05-17 CA CA002447052A patent/CA2447052A1/en not_active Abandoned
- 2002-05-17 EP EP02769769A patent/EP1399462A4/en not_active Withdrawn
- 2002-05-17 US US10/151,008 patent/US20030087861A1/en not_active Abandoned
- 2002-05-17 NZ NZ530101A patent/NZ530101A/en unknown
- 2002-05-17 JP JP2002589500A patent/JP2004537517A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537517A5 (enExample) | ||
| US11466274B2 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP2002540137A5 (enExample) | ||
| JP2018518201A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| KR20010080098A (ko) | 만성 ｃ형 간염 환자에서 검출 가능한 ｈｃｖ-ｒｎａ를제거하기 위한 리바비린-인터페론 알파 복합 치료 방법 | |
| UA44253C2 (uk) | Похідні фосфономоноефірів нуклеїнових кислот та олігонуклеотидвмісні похідні фосфономоноефірів нуклеїнових кислот | |
| JP2008509701A5 (enExample) | ||
| EP0618923A1 (en) | Peptide nucleic acids and their effect on genetic material | |
| CN116348150A (zh) | 用于递送治疗剂的脂质缀合物 | |
| RU96107392A (ru) | Фотосенсибилизаторы | |
| JP4789095B2 (ja) | ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤 | |
| JP2004523478A5 (enExample) | ||
| JP2002523496A5 (enExample) | ||
| JPH02160769A (ja) | 新規な２′―ハロメチリデン、２′―エテニリデン及び２′―エチニルアデノシン誘導体類 | |
| CA2486872A1 (en) | Nf-kb inhibitors and uses thereof | |
| EP3083650B1 (en) | Novel ferrocenyl compounds | |
| JP2006515854A5 (enExample) | ||
| JPWO2023034818A5 (enExample) | ||
| CN1278261A (zh) | 新型喜树碱衍生物 | |
| Buhr et al. | Synthesis of a tetracyclic 2′-deoxyadenosine analog | |
| CN107722010A (zh) | 一种含有硝基咪唑基团的低氧激活氯乙基亚硝基脲及其制备方法和应用 | |
| JP2007500205A5 (enExample) | ||
| JP2004518633A5 (enExample) | ||
| JPWO2023178230A5 (enExample) |